The Ocular Implants market is forecast to grow at a CAGR of 14.1%, reaching USD 40.1 billion in 2031 from USD 20.7 billion in 2026.
The ocular implant market is driven by the rising prevalence of eye conditions such as cataracts, glaucoma, scleritis, and age-related macular degeneration (AMD). The World Health Organization estimates 2.2 billion people globally have vision impairment, with cataracts and AMD among the leading causes. This surge fuels demand for ocular implants, critical for surgical procedures like cataract surgery and glaucoma treatment. Advancements in ophthalmic diagnostic technology, including optical coherence tomography (OCT), enhance early detection, increasing the need for intraocular lenses, glaucoma drainage devices, and artificial eye devices.
Improved accessibility to online resources educates patients about eye treatment options, boosting market growth. Technological developments in ocular implants, such as premium intraocular lenses and minimally invasive glaucoma surgery (MIGS) devices, improve outcomes and drive adoption. North America leads due to advanced healthcare infrastructure, while Asia-Pacific grows rapidly, driven by aging populations and rising healthcare access in countries like India and China.
Challenges include high implant costs and limited access in developing regions, but government initiatives and NGO programs, like WHO’s Vision 2030, promote eye care. Innovations in biocompatible materials and smart implants with sensors enhance patient outcomes. The ocular implant market thrives on technological innovation, rising eye disease prevalence, and global healthcare advancements, ensuring sustained growth in addressing vision impairment.
Rising demand for glaucoma implants
The market growth can be attributed to the fact that glaucoma is becoming more common and is one of the main causes of blindness. A Bright Focus Foundation study estimates that 20 million individuals worldwide suffered from glaucoma in 2020. By the end of 2040, this number is anticipated to surpass 111 million. The ocular implants market is divided into intraocular lenses, corneal implants, orbital implants, glaucoma implants, ocular prostheses, and other categories based on the product type.
During the forecast period, glaucoma implants are expected to continue to increase the market demand. This is because governmental and non-governmental organizations have raised awareness of glaucoma. For example, to raise awareness about glaucoma, the World Glaucoma Association[1] has launched an initiative called "World Glaucoma Week," scheduled for March 6–12, 2022. Moreover, they have been used for so long to treat nearsightedness, farsightedness, and presbyopia that intraocular lenses have become increasingly popular.
The increasing importance of aesthetic value has led to a rise in the adoption of ocular prosthesis
For those who have experienced eye trauma, the ocular prosthesis adds aesthetic value to their faces. The market offers a wide range of implantable ocular prostheses composed of a scleral shell, acrylic, and glass. The use of cryolite glass ocular prostheses is becoming more and more popular. This is because the glass provides a reflection that resembles the human eye. Furthermore, the development of digital technology has made it possible to quickly and accurately construct an ocular prosthesis of this kind. In developed nations like the United States, Germany, and Japan, the acceptance of glass ocular prostheses has shifted due to these factors.
Increasing prevalence of eye disorders like cataracts and glaucoma
The two most common ocular conditions affecting the world's elderly population are cataracts and glaucoma. The World Health Organization (WHO) estimates that cataracts cause blindness in about 20 million people globally. Furthermore, it is estimated that only 17% of people with cataract-related vision impairment and 36% of people with refractive error-related distance vision impairment worldwide have access to the proper interventions. Glaucoma devices and intraocular lenses have become more popular due to this increase. In conjunction with the aforementioned factors, the population's growing awareness of various treatment options is expected to support the ocular implant market growth in the foreseeable future.
Rising technological advancements
There have been many technological developments in the market. For example, the PRIMA System, a bionic or artificial eye technology that partially replaces the physiological function of the eye's photoreceptors, was recently introduced by PIXIUM VISION. A wireless sub-retinal implant that sends visual data to the brain's optical nerve makes this possible. The gadget also includes a digital projector, a pair of glasses with a camera integrated into them, and a pocket processor. A feasibility study for this technology is presently being conducted in the United States and France for people with age-related macular degeneration (dry atopic form), which causes severe vision loss.
Furthermore, developing microinvasive glaucoma devices for patients is anticipated to propel the market. Advanced intraocular lenses and corneal implants that solve issues with currently available implantable devices are two more examples of such innovations. During the projected years, the market sales of these cutting-edge technologies for treating ocular disorders and diseases are anticipated to soar.
High demand for ocular implants in hospitals
This is because more patients choose to have eye surgeries in hospitals than in clinics or other settings. Two factors driving the growth of the hospital segment are the rising prevalence of cataract and glaucoma surgeries in hospitals and the growing number of people undergoing ocular surgeries. The need for ocular implants in hospitals is expected to be fueled by other significant factors, such as the developing healthcare infrastructure in developing nations and the rise in sophisticated healthcare facilities. By the end of the forecast period, it is anticipated that this market trend will be followed.
North America is witnessing exponential growth during the forecast period
North America is anticipated to grow at a high rate because of the rising incidence of eye problems, sedentary lifestyles, and rising knowledge of important factors.
The factor that is primarily driving the market boom in North America is Trelease products. Additionally, the region's access to technologically advanced products and a favourable pay environment make it likely for the company to maintain its lead over the course of the forecast period.
February 2026: Ocular Therapeutix reported updated clinical milestones for AXPAXLI™ (OTX-TKI) wet AMD Phase 3 SOL-1 trial with topline data expected at the 49th Macula Society Annual Meeting.
October 2025: Scientists demonstrated a wireless retinal implant restoring central vision in geographic atrophy AMD patients, partially restoring functional vision in clinical research published in 2025.
October 2025: U.S. FDA approved Glaukos’ Epioxa keratoconus therapy, a new less-invasive treatment expected to be commercially available in early 2026, improving patient comfort and clinical outcomes.
March 2025: Neurotech Pharmaceuticals received FDA approval for Encelto, the first encapsulated cell therapy implant treating idiopathic macular telangiectasia (MacTel) type 2, offering a novel sustained treatment option.
SMR Ophthalmic Pvt. Ltd.
iSTAR Medical
Johnson & Johnson
STAAR Surgical
Alcon
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 20.7 billion |
| Total Market Size in 2031 | USD 40.1 billion |
| Forecast Unit | Billion |
| Growth Rate | 14.1% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Type, End-User, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|